Kevin Halling, MD, PhD, discussed the clinical utility of RNA-sequencing methods in patients with cancer at the 2019 Association for Molecular Pathology Annual Meeting and Expo. Halling says RNA sequencing is a very powerful diagnostic technique.
Kevin Halling, MD, PhD, a consultant in the Division of Laboratory Genetics and Genomics and Department of Laboratory Medicine and Pathology at the Mayo Clinic, discussed the clinical utility of RNA-sequencing methods in patients with cancer at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo. Halling says RNA sequencing is a very powerful diagnostic technique.
According to Halling, these methods can be used to detect not only gene fusions in patients with cancer, but RNA sequencing can also detect point mutations and small indels. Additionally, pathologists can use RNA sequencing techniques to measure gene expression in the patient’s tumors.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More